U.S. Pulmonary Drug Delivery Devices Market Revenue & Forecast Analysis, 2026-2035

The American Lung Association reports that millions of individuals in the United States experience chronic respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), leading to a constant need for effective inhaled medication treatments. The increasing occurrence of respiratory conditions, higher usage of inhalers and nebulizers, expanding acceptance of specialized pulmonary drug delivery systems, and progress in intelligent and digitally linked inhalation devices are propelling the growth of the U.S. pulmonary drug delivery devices market.

The U.S. pulmonary drug delivery devices market has witnessed steady historical growth, supported by the increasing prevalence of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. Growing utilization of inhaled therapies, rising patient preference for convenient drug administration, and continuous improvements in inhalers and nebulizers have strengthened demand for pulmonary drug delivery devices. For instance, the increasing use of metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) for long-term management of asthma and COPD has supported sustained device demand across U.S. respiratory care settings.

The market is expected to maintain strong growth during the forecast period, driven by increasing adoption of smart inhalers, connected drug delivery technologies, advanced nebulizers, and next-generation inhalation systems. The growing development of biologic and high-value respiratory therapies is also encouraging manufacturers to improve dose precision, delivery efficiency, and device usability. For instance, the integration of sensors and Bluetooth connectivity into inhalation devices is enabling medication-use tracking and adherence monitoring, supporting the transition toward digitally connected respiratory care in the U.S.

U.S. Pulmonary Drug Delivery Devices Market Overview

Base Year Market Size (2025): USD 23.7 Billion

CAGR: 4.9%

Forecast Year Market Size (2035): USD 37.8 Billion

Major Players:

• Boehringer Ingelheim

• Kindeva Drug Delivery

• ResMed

• Teva Pharmaceutical Industries

• Vectura Fertin Pharma

U.S. Pulmonary Drug Delivery Devices Market Trends

The U.S. pulmonary drug delivery devices market is witnessing notable advancements, driven by the growing adoption of smart inhalers, development of next-generation inhalation technologies, increasing demand for personalized respiratory care, and the shift toward convenient home-based treatment.

· One of the key trends is the increasing adoption of smart and connected inhalers, which incorporate sensors, Bluetooth connectivity, and mobile applications to monitor medication use, provide reminders, and support adherence. These technologies are particularly relevant for patients requiring long-term asthma and COPD management.

· Manufacturers are increasingly developing low-impact and environmentally sustainable inhalation devices, particularly as healthcare providers and pharmaceutical companies seek alternatives with lower environmental footprints. This trend is encouraging innovation in propellants, device materials, and manufacturing processes.

· The market is also witnessing increased interest in advanced nebulization technologies, including portable and vibrating-mesh nebulizers, which offer compact designs and efficient aerosol generation. These devices are gaining attention for patients who have difficulty using conventional inhalers or require liquid-based therapies.

· Furthermore, the growing development of biologic and high-value respiratory therapies is encouraging innovation in pulmonary delivery platforms capable of providing accurate and consistent administration of complex formulations. Device-drug combination products are becoming increasingly important in the development of advanced respiratory treatments.

Collectively, the rising use of smart inhalers, progress in DPI and MDI technologies, tailored respiratory treatment, eco-friendly device innovation, and expansion in portable nebulization options are significant trends influencing the future of the U.S. pulmonary drug delivery devices market.

U.S. Pulmonary Drug Delivery Devices Market Analysis

By Product Type

Inhalers dominate the U.S. pulmonary drug delivery devices market due to their widespread use in asthma and COPD management, portability, and ease of administration.

Based on product type, the U.S. pulmonary drug delivery devices market is categorized into inhalers, nebulizers, and accessories. The inhalers segment holds the largest market share in 2025.

By Application

Chronic obstructive pulmonary disease (COPD) dominates the U.S. pulmonary drug delivery devices market due to the high prevalence of the disease and the widespread use of inhaled therapies for long-term symptom management.

Based on application, the U.S. pulmonary drug delivery devices market is categorized into asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, and others. The chronic obstructive pulmonary disease (COPD) segment holds the largest market share in 2025.

By End-use

Hospitals dominate the U.S. pulmonary drug delivery devices market due to their high patient volumes, advanced respiratory care infrastructure, and ability to manage complex pulmonary conditions.

Based on end-use, the U.S. pulmonary drug delivery devices market is categorized into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment holds the largest market share in 2025.